Skip to main content
Clinical Trials/NL-OMON53636
NL-OMON53636
Recruiting
Phase 2

Exercise during Neoadjuvant chemoradiation Treatment to improve rectal and esophageal cancer Outcome - pilot trial. - EXENTRO

Fysiologie0 sites39 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
rectal and oesophageal cancer
Sponsor
Fysiologie
Enrollment
39
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Fysiologie

Eligibility Criteria

Inclusion Criteria

  • \- Diagnosed with rectal or esophageal carcinoma
  • \- Patients with rectal or esophageal carcinoma need to be scheduled for
  • treatment with neoadjuvant chemoradiation therapy
  • Oral capecitabine combined with concurrent radiotherapy (50 Gy in 25
  • fractions) for rectal cancer
  • CROSS regimen (carboplatin, paclitaxel with concurrent 41\.4 Gy in 23
  • fractions radiation) for esophageal cancer
  • \- Aged \> 18 years

Exclusion Criteria

  • A participant who meets any of the following criteria will be excluded from
  • participation in this study:
  • \- Unable to perform basic activities of daily living such as walking or biking
  • \- Presence of other disabling co\-morbidity that might hamper or endanger
  • physical exercise e.g. heart failure, chronic obstructive pulmonary disease,
  • orthopaedic conditions and neurological disorders
  • \- Presence of cognitive disorders or severe emotional instability (e.g.,
  • Schizophrenia, Alzheimer, alcohol addiction)
  • \- Immunodeficiency (primary or secondary)
  • \- Insufficient mastery of the Dutch language

Outcomes

Primary Outcomes

Not specified

Similar Trials